Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuaki Anami

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 17, 2026
CD44v9 as a therapeutic target for antibody-drug conjugate in advanced breast cancerDileep R Reddy, McKenna E Flynn, Yasuaki Anami, et al.
Molecular Cancer Therapeutics|March 7, 2025
177Lu-Labeled Antibody-Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid TumorsAiko Yamaguchi, Chisato M Yamazaki, Yasuaki Anami, et al.
Antibody Therapeutics|April 14, 2026
Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody-drug conjugatesAiko Yamaguchi, Junping Hong, Leike Li, et al.
Molecular Cancer Therapeutics|July 6, 2022
An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug ConjugatesSummer Y Y Ha, Yasuaki Anami, Chisato M Yamazaki, et al.
Cancer Research|December 18, 2024
Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal CancerJoan Jacob, Yasuaki Anami, Peyton C High, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal CancerJoan Jacob, Yasuaki Anami, Peyton High, et al.
Cancer Immunology Research|June 20, 2019
Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML DevelopmentXun Gui, Mi Deng, Hao Song, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 17, 2026
CD44v9 as a therapeutic target for antibody-drug conjugate in advanced breast cancerDileep R Reddy, McKenna E Flynn, Yasuaki Anami, et al.
Molecular Cancer Therapeutics|March 7, 2025
177Lu-Labeled Antibody-Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid TumorsAiko Yamaguchi, Chisato M Yamazaki, Yasuaki Anami, et al.
Antibody Therapeutics|April 14, 2026
Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody-drug conjugatesAiko Yamaguchi, Junping Hong, Leike Li, et al.
Molecular Cancer Therapeutics|July 6, 2022
An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug ConjugatesSummer Y Y Ha, Yasuaki Anami, Chisato M Yamazaki, et al.
Cancer Research|December 18, 2024
Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal CancerJoan Jacob, Yasuaki Anami, Peyton C High, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal CancerJoan Jacob, Yasuaki Anami, Peyton High, et al.
Cancer Immunology Research|June 20, 2019
Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML DevelopmentXun Gui, Mi Deng, Hao Song, et al.
Pageof 3